Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 3,890.00
-130.00 (-3.23%)
Nov 2, 2026, 3:30 PM KST
Prestige BioPharma Market Cap
Prestige BioPharma has a market cap or net worth of 46.75 billion as of October 30, 2026. It is the 32,822nd most valuable company in the world and the 1,852nd biggest in South Korea. Its market cap has decreased by 68.81% in one year.
Market Cap
46.75B
Enterprise Value
159.90B
Revenue
26.07B
Global Rank
Country Rank
#1,852 South Korea
PE Ratio
n/a
ChartMarket Cap Chart
Since May 28, 2021, Prestige BioPharma's market cap has decreased from 360.58B to 46.75B, a decrease of -87.03%. That is a compound annual growth rate of -31.33%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 2, 2026 | 46.75B | -69.73% |
| Dec 30, 2025 | 154.45B | -14.96% |
| Dec 30, 2024 | 181.61B | 59.39% |
| Dec 28, 2023 | 113.94B | 29.33% |
| Dec 29, 2022 | 88.10B | -64.84% |
| Dec 30, 2021 | 250.60B | -30.50% |
| May 28, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Anterogen.Co.,Ltd. | 133.68B |
| MedPacto | 104.54B |
| Genexine | 98.24B |
| Vaxcell-Bio Therapeutics | 86.63B |
| iNtRON Biotechnology | 86.19B |
| Amicogen | 64.54B |
| ENCell | 51.56B |
| GeneOne Life Science | 48.42B |